Meds & supplements › Apalutamide
Medicine
Apalutamide
ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC) ERLEADA is an androgen receptor inhibitor indicated for the…
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- Metastatic castration-sensitive prostate cancer (mCSPC)
- Non-metastatic castration-resistant prostate cancer (nmCRPC)
What it is used for
ERLEADA is indicated for the treatment of patients with
- Metastatic castration-sensitive prostate cancer (mCSPC)
- Non-metastatic castration-resistant prostate cancer (nmCRPC)
Side effects, and when to stop
The following are discussed in more detail in other sections of the labeling:
- Cerebrovascular and Ischemic Cardiovascular Events.
- Fractures.
- Falls.
- Seizure.
- Severe Cutaneous Adverse Reactions (SCARs).
- Interstitial Lung Disease (ILD).
Storing it
Storage and Handling
Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted to 15 °C to 30 °C (59 °F to 86 °F).
Store in original package to protect from light and moisture. Do not discard desiccant.
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. Apalutamide; [reviewed 2026 Aug 2; cited 2026 Nov 11]. Available from: https://sofidex.com/patients/medicines/apalutamide
- APA 7th
sofidex. (2026, August 2). Apalutamide. Daloreum. Retrieved November 11, 2026, from https://sofidex.com/patients/medicines/apalutamide
- AMA 11th
Apalutamide. sofidex. Reviewed August 2, 2026. Accessed November 11, 2026. https://sofidex.com/patients/medicines/apalutamide
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.